Conference abstractPublished 23 Jun 2025

Exploring signature proteins to design a novel multi-epitope vaccine candidate against Mycobacterium tuberculosis: An in-silico approach

Authors: Haleema Fayaz

Sharda University, Greater Noida, Uttar Pradesh, India

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Mycobacterium tuberculosis (M.tb), a highly infectious bacterium, remains a major global health threat, causing tuberculosis, a disease responsible for millions of deaths annually. The emergence of drugresistant strains has further complicated efforts to control this deadly infection. While the Bacillus Calmette- Guérin (BCG) vaccine is the only available option, its efficacy in preventing adult pulmonary tuberculosis is limited. To address this pressing need, we have proposed a novel multi-epitope vaccine (MEV) strategy. This approach involves the combination of epitopes from four key M.tb proteins that are known to elicit robust immune responses. Two MEV constructs were designed, each paired with a different TLR-binding adjuvant: Laterosporulin (TLR-4) and PorB (TLR-2). Computational analysis of the MEV constructs revealed favorable physicochemical properties and strong interactions with TLR receptors, suggesting their potential to trigger a robust immune response. Immunological simulations further supported this prediction. To enhance the vaccine's efficacy, codon optimization and in-silico cloning were employed. The study's findings indicate that the MEV holds promise as a potential solution to combat M.tb. However, rigorous in-vitro and in-vivo validation is essential to assess its safety, efficacy, and immunogenicity before it can be considered for clinical trials and widespread deployment. In conclusion, this study presents a promising approach to combat TB by developing multi-epitope vaccines. Further research is necessary to translate these computational designs into tangible solutions for global health.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Longdom does not store it.

Try:

More from this journal

The newest in Journal of Antivirals & Antiretrovirals.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Antivirals & Antiretrovirals
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Haleema Fayaz”